← board
TIL
distress 1/10 · well-funded / low risk$7.30+1%today-77% from 52w high
Lead: first-line NSCLC
Revenue
pre-revenue
Liquidity
$150M
Runway
4.4 yrs
Shares 1y
+1%
Price & events
+3.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.7%
1D
-2.8%
1W
-3.4%
1M
-10.8%
3M
+2.2%
6M
-75.4%
1Y
-42.2%
2Y
-98.1%
5Y
-98.6%
All
Overview
- Market Cap
- $49.51M
- Volume
- 912
- 52 Week Range
- $6.66 – $32.24
- Total Shares
- 6.78M
- Float Shares
- 3.62M
- Short %
- 5.83%
- % Held by Insiders
- 6.56%
- % Held by Institutions
- 62.09%
- RVOL
- 0.06x
- Beta
- 1.91
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- mid-2026trial initiationsecondaryPhase 3IMM2510/AXN-2510 · Phase 3 trial anticipated to start in mid-2026 in ChinaSEC 8-K
- before end of 2025trial initiationsecondaryPhase 1/2IMM2510/AXN-2510 · Phase 1b/2 trial in US expected to initiate before end of 2025SEC 8-K
- 2H 2025readoutPhase 2IMM2510/AXN-2510 · Initial safety and efficacy results anticipated in second half of 2025SEC 8-K
- Q3 2025enrollment completesecondaryPhase 2IMM2510/AXN-2510 · Enrollment of ~60 patients expected to complete in Q3 2025SEC 8-K
- 2024-09-16partnershipSYN-2510/IMM2510 · Global registrational strategy for PD-L1xVEGF bispecific antibody in non-small cell lung cancer and triple-negative breast cancerSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $7 (-4% upside) · 1 analysts
- 2026-01-07HC Wainwright & Co.Buy → Neutral
- 2025-09-11HC Wainwright & Co.Buy
- 2025-08-27HC Wainwright & Co.Buy
- 2025-08-15HC Wainwright & Co.Buy
- 2025-06-05HC Wainwright & Co.Buy
- 2025-06-02JMP SecuritiesMarket Perform
Competitors — first-line NSCLC
Recent news
- 2026-07-23Avoiding Lag: Real-Time Signals in (TIL) Movement - Stock Traders Daily
- 2026-07-21Jelly Roll’s Daughter Teases Explosive Truth Behind Bunnie Xo Divorce: ‘Wait ‘Til Y’all Find Out’ - Yahoo
- 2026-07-21Jelly Roll’s daughter Bailee Ann talks about the reason behind his divorce from Bunnie Xo: ‘Wait ‘til y’a - The Times of India
- 2026-07-20“Wait ‘Til You Find Out” — Jelly Roll’s Daughter Says The Internet Will “Crumble” If She Reveals What Really Happened Between Her Dad & Bunnie Xo - Whiskey Riff
- 2026-07-20Three friends, three harmonies, one great summer night: 'Til Sunday brings sweet music to Heritage Park - The Herald Journal
- 2026-07-20Vingegaard Out of the Tour: “You Don’t Know What You’ve Got ’til It’s Gone” - Škoda We Love Cycling
- 2026-07-20Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors - Clinical Leader
- 2026-07-20Correction: Opjustering af forventningerne til 2026 (ukorrekt kategori) - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.